Investor Wants Obagi To Put Itself Up For Sale and 4 Other Stocks On The Move
Obagi (NASDAQ:OMPI): Activist investor David Callan, who holds a large share of Obagi stock, and author Scott Matusow both want the skin care company to put itself up for sale. They believe that the firm is too small to attain their worldwide potential. Callan, who has already pushed for the sales of E-Z-EM and SRI/Surgical Express, will continue to take aggressive steps.
Rosetta Genomics (NASDAQ:ROSG): After Rosetta Genomics announced the commercial launch of the miRview mets assay, their flagship product in the United States’ oncology market, shares increased by 4.7%. MiRview mets2 is used as a diagnostic tool in the evaluation of cancer patients.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Illumina (NASDAQ:ILMN): The United Kingdom’s Times newspaper reported that Roche may make another bid for the company at $60 a share. Illumina had previously rejected a $51 bid from Roche this past April. Shares increased by 7.1% to $52.44.
ARIAD Pharmaceuticals (NASDAQ:ARIA): After announcing initial results from Phase 1/2 tests on their Investigational Tyrosine-Kinase Inhibitor, AP26113, in patients with advanced non- small cell lung cancer, Ariad Pharmaceutical’s stock rose by 0.4%. The company made a statement saying that there was “compelling clinical evidence,” of anti-tumor activity at multiple dose levels. Today, these results are being presented to the Congress of the European Society for Medical Oncology in Vienna, Austria.
DaVita (NYSE:DVA): Berkshire Hathaway raised their stake in DaVita to about 10.8% and the House of Buffett bought another 282,000 shares. This brought the total amount of holdings to about 10,200,000 shares.
Don’t Miss: What’s Next for Pfizer?